Clinical Trials on Leukemia, B-Cell

Total 38055 results

Stephan Grupp MD PhD
Children's Hospital of Philadelphia

Recruiting

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

B Cell Acute Lymphoblastic Leukemia (B-ALL) | B Lineage Lymphoblastic Lymphoma

United States
BeiGene

Recruiting

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

Australia, United States, New Zealand, Korea, Republic of, Canada, Puerto Rico
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Lymphoma, Non-Hodgkin | B-cell Lymphoma | Multiple Myeloma | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, B-cell Marginal Zone

United States, France, Poland, Italy
Shenzhen Second People's Hospital
Shenzhen Institute for Innovation and Translational Medicine

Unknown

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia | Small-Cell Lymphoma

United States, Australia, Austria, Belgium, Canada, Czechia, France, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Sweden, Turkey, United Kingdom
Boryung Pharmaceutical Co., Ltd

Active, not recruiting

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Follicular Lymphoma | B Cell Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Small Lymphocytic Leukemia

Korea, Republic of, United States
Institut Paoli-Calmettes

Recruiting

Institut Paoli Calmettes Chronic Lymphatic Leukemia Database

Leukemia, Lymphocytic, Chronic, B-Cell

France
Boehringer Ingelheim

Completed

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Leukemia, Lymphocytic, Chronic, B-Cell

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Leukemia, Lymphocytic, Chronic, B-Cell

Spain, Poland
Peking University People's Hospital
Beijing Hospital

Unknown

Treatment of Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell
Peking University People's Hospital
Beijing Hospital

Unknown

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Leukemia, Lymphocytic, Chronic, B-Cell
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Leukemia, Lymphoblastic, Chronic

Italy
National Cancer Institute (NCI)

Terminated

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Wuhan Union Hospital, China
Beijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.

Recruiting

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

T-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin Lymphoma

China
Leslie Andritsos
Celgene Corporation

Completed

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States
Newave Pharmaceutical Inc

Recruiting

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Hairy Cell Leukemia | CLL/SLL

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | CLL (Chronic Lymphocytic Leukemia) | Monoclonal B-Cell Lymphocytosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Childhood Acute Lymphoblastic Leukemia | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Prolymphocytic Leukemia | Refractory Chronic... and other conditions

United States, Denmark
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (VIS)

Chronic Lymphocytic Leukemia | High Risk CLL

Italy
iOMEDICO AG

Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms (RUBIN)

Chronic Lymphocytic Leukemia (CLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL) | Waldenström's Macroglobulinemia (WM)

Germany
French Innovative Leukemia Organisation
Roche Pharma AG; Janssen-Cilag Ltd.

Completed

Phase II Trial GA101 Inbrutinib B CLL (ICLL07GAI)

Leukemia, Lymphocytic, Chronic, B-Cell

France
Arbeitsgemeinschaft medikamentoese Tumortherapie
Roche Pharma AG; Celgene Corporation

Completed

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Leukemia, Lymphocytic, Chronic, B-Cell

Austria
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small Lymphocytic | CLL | SLL | Small-Cell Lymphoma | Leukemia, Chronic Lymphocytic

Italy, Argentina, Chile, Brazil, Israel, South Africa, United States, Australia, Puerto Rico, Spain, Canada, Germany, France, United Kingdom, Colombia
New York Medical College

Completed

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia (MITCL)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Acute Myelogenous Leukemia | Diffuse Large B-cell Lymphoma | Burkitt Lymphoma/Leukemia

United States
University College London Hospitals

Completed

CAR T Cell Therapy Related Cardiovascular Outcomes (CARTCO)

Cardiovascular Diseases | Diffuse Large B Cell Lymphoma | Cardiotoxicity | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | B-cell Lymphoma Refractory | Cardiovascular Complication | B-cell Lymphoma Recurrent

United Kingdom
Shanghai Ming Ju Biotechnology Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University

Not yet recruiting

Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL

Leukemia, Lymphocytic, Chronic, B-Cell

China
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Georgia, Bulgaria, Poland
Jennifer Woyach
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Active, not recruiting

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China
M.D. Anderson Cancer Center

Terminated

A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach

Leukemia, Lymphocytic, Chronic

United States
Hoffmann-La Roche

Completed

A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CaLLypso)

Lymphocytic Leukemia, Chronic

Greece
Hoffmann-La Roche

Completed

A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Israel
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.

Lymphocytic Leukemia, Chronic

Italy
Genentech, Inc.

Completed

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Lymphocytic Leukemia, Chronic

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Terminated

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

United States
Hoffmann-La Roche

Completed

A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Lymphocytic Leukemia, Chronic

Finland, France, Spain, Portugal, Turkey, United Kingdom, Sweden, Tunisia
Eisai Inc.

Completed

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic

Canada, Australia, United States, Argentina, Brazil
French Innovative Leukemia Organisation

Recruiting

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Chronic Lymphoid Leukemia

France
Jennifer Woyach

Active, not recruiting

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Jewish General Hospital
Novartis Pharmaceuticals

Terminated

Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients (GL-CLB-001)

Chronic Lymphocytic Leukemia

Canada
Hoffmann-La Roche

Completed

A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities

Chronic Lymphocytic Leukemia

Greece
TG Therapeutics, Inc.

Completed

Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

Chronic Lymphocytic Leukemia

United States
Gilead Sciences
German CLL Study Group

Completed

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Gilead Sciences
German CLL Study Group

Completed

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Oncology Institute of Southern Switzerland
Azienda Ospedaliero Universitaria Maggiore della Carita

Completed

A Prognostic Tool for Early Stage CLL

Chronic Lymphocytic Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

Chronic Lymphocytic Leukemia

Italy
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

Chronic Lymphocytic Leukemia

United States
Celgene

Completed

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Chronic Lymphocytic Leukemia

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation

Chronic Lymphocytic Leukemia

United States

Clinical Trials on Leukemia, B-Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations